Skip to main content

Advertisement

Erratum to: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Article metrics

  • 1384 Accesses

The original article was published in Journal of Experimental & Clinical Cancer Research 2012 31:73

Correction

After the publication of this work[1], we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’, apart from the last paragraph in the Introduction section which should remain as published.

We also noticed in the first sentence of the second paragraph of the Materials and methods section we mistakenly stated that OGX-011 (ASO-CLU) was purchased from OncoGenex Technologies. As ASO-CLU is currently in the clinical testing phase, it is not available for sale from OncoGenex Technologies. The corrected sentence should read:

ASO-CLU was acquired from OncoGenex Technologies.

We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.

References

  1. 1.

    Tang Y, Liu F, Zheng C, Sun S, Jiang Y: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res. 2012, 31: 73-10.1186/1756-9966-31-73.

Download references

Author information

Correspondence to Shaochuan Sun.

Additional information

The online version of the original article can be found at 10.1186/1756-9966-31-73

Yong Tang, Fenghua Liu contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article